Clinical Trials Directory

Trials / Completed

CompletedNCT05258123

Ginkgo Biloba Extract in the Treatment of Schizophrenia

The Effects of Ginkgo Biloba Extract in the Treatment of Schizophrenia

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Beijing HuiLongGuan Hospital · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia

Detailed description

Objective: This study aimed to evaluate the effect of Ginkgo biloba extract in the treatment of symptoms and cognitive functioning in 200? chronic patients with schizophrenia Methods: 1. Clinical Trial: This is a randomized, double-blind and parallel controlled trial in the chronic patients with schizophrenia. The study consists of 12 weeks of double-blind treatment. 2. Assessment Procedures: 2.1 Primary Outcome Variable: Patients were assessed by two clinical trained staff, who were blind to the treatment protocols, by using the Positive and Negative Syndrome Scale (PANSS) to assess the psychopathology and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to evaluation the cognitive functioning. Patients were interviewed at screening, and at baseline, 4? weeks, 12? weeks. 2.2 Side effects: The side effect rating scale (UKU) was used to assess the side effect at baseline, 4? weeks, and 12? weeks. 2.3 Weight gain measurement: weigh was measured every week.

Conditions

Interventions

TypeNameDescription
DRUGGinkgo Biloba ExtractGinkgo biloba extract with 360mg was administered
DRUGPlacebo oral tabletPlacebo with nine tables was administered

Timeline

Start date
2017-05-15
Primary completion
2018-06-12
Completion
2018-08-15
First posted
2022-02-28
Last updated
2022-02-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05258123. Inclusion in this directory is not an endorsement.